Roche Boosts Drug Research with New AI Supercomputers
羅氏藥廠以新款人工智慧超級電腦強化藥物研發
On March 16, 2026, the pharmaceutical giant Roche announced a major expansion of its global AI infrastructure, signaling a bold shift toward becoming an AI-accelerated healthcare organization.
2026年3月16日，製藥巨頭羅氏（Roche）宣布大規模擴展其全球人工智慧基礎設施，標誌著其大膽轉型為一家「人工智慧加速型」的醫療保健組織。
By integrating 2,176 NVIDIA Blackwell GPUs, Roche now operates one of the industry's largest hybrid-cloud AI factories.
藉由整合2,176顆NVIDIA Blackwell GPU，羅氏現已營運業內規模最大的混合雲人工智慧工廠之一。
This initiative, built on a long-standing partnership with NVIDIA, is designed to drastically reduce the traditional 10-to-15-year timeline for drug development.
這項建立在與NVIDIA長期合作基礎上的計劃，旨在大幅縮短傳統藥物開發需耗時10至15年的時程。
Using the BioNeMo platform, Roche employs a Lab-in-the-Loop strategy that combines AI-driven predictions with real-world wet lab verification to improve drug discovery.
透過使用BioNeMo平台，羅氏採用了一種「實驗室迴路」（Lab-in-the-Loop）策略，結合人工智慧驅動的預測與現實世界的濕實驗室驗證，以改進藥物發現。
Beyond research, the company uses digital twins through NVIDIA Omniverse to optimize manufacturing, while Parabricks streamlines genomic analysis.
除了研究之外，該公司亦利用NVIDIA Omniverse的數位孿生（Digital Twins）技術來優化製造流程，同時使用Parabricks簡化基因組分析。
Roche’s Chief Digital Officer, Wafaa Mamilli, emphasizes that time is the most critical variable in medicine.
羅氏首席數位長Wafaa Mamilli強調，時間是醫學中最關鍵的變數。
By leveraging these high-performance computational tools, Roche aims to tackle the high failure rates in drug discovery and enhance efficiency across its entire value chain.
透過運用這些高效能計算工具，羅氏目標在於應對藥物開發中的高失敗率，並提升其整個價值鏈的效率。
As pharma companies increasingly adopt AI as core infrastructure, Roche’s move reflects a broader industry trend of prioritizing computational power to accelerate life-saving medical breakthroughs.
隨著製藥公司日益將人工智慧視為核心基礎設施，羅氏的舉措反映了整個產業優先投入計算能力以加速挽救生命之醫療突破的趨勢。
